全文获取类型
收费全文 | 3521篇 |
免费 | 313篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 120篇 |
儿科学 | 56篇 |
妇产科学 | 74篇 |
基础医学 | 447篇 |
口腔科学 | 96篇 |
临床医学 | 291篇 |
内科学 | 604篇 |
皮肤病学 | 82篇 |
神经病学 | 246篇 |
特种医学 | 215篇 |
外科学 | 627篇 |
综合类 | 219篇 |
一般理论 | 2篇 |
预防医学 | 134篇 |
眼科学 | 87篇 |
药学 | 284篇 |
中国医学 | 28篇 |
肿瘤学 | 281篇 |
出版年
2023年 | 23篇 |
2022年 | 71篇 |
2021年 | 121篇 |
2020年 | 67篇 |
2019年 | 72篇 |
2018年 | 95篇 |
2017年 | 79篇 |
2016年 | 124篇 |
2015年 | 118篇 |
2014年 | 116篇 |
2013年 | 188篇 |
2012年 | 246篇 |
2011年 | 230篇 |
2010年 | 147篇 |
2009年 | 123篇 |
2008年 | 167篇 |
2007年 | 206篇 |
2006年 | 163篇 |
2005年 | 167篇 |
2004年 | 161篇 |
2003年 | 128篇 |
2002年 | 104篇 |
2001年 | 88篇 |
2000年 | 108篇 |
1999年 | 81篇 |
1998年 | 68篇 |
1997年 | 45篇 |
1996年 | 38篇 |
1995年 | 43篇 |
1994年 | 35篇 |
1993年 | 28篇 |
1992年 | 25篇 |
1991年 | 30篇 |
1990年 | 35篇 |
1989年 | 51篇 |
1988年 | 37篇 |
1987年 | 35篇 |
1986年 | 27篇 |
1985年 | 22篇 |
1984年 | 27篇 |
1983年 | 20篇 |
1982年 | 12篇 |
1981年 | 18篇 |
1980年 | 20篇 |
1979年 | 7篇 |
1978年 | 11篇 |
1977年 | 10篇 |
1976年 | 7篇 |
1975年 | 11篇 |
1968年 | 6篇 |
排序方式: 共有3893条查询结果,搜索用时 12 毫秒
41.
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. 总被引:19,自引:0,他引:19
Jens Koopmann Neal S Fedarko Alka Jain Anirban Maitra Christine Iacobuzio-Donahue Ayman Rahman Ralph H Hruban Charles J Yeo Michael Goggins 《Cancer epidemiology, biomarkers & prevention》2004,13(3):487-491
OBJECTIVES: Pancreatic adenocarcinoma is a deadly disease with an overall 5-year patient survival of less than 5%. This dismal prognosis of pancreatic cancer is largely due to the advanced stage of the disease at presentation. If pancreatic cancer could be diagnosed more readily and accurately using serum markers, patient survival could theoretically be improved by enabling more patients to avail of surgical resection. One candidate tumor marker recently identified by global gene expression analysis of pancreatic cancer is the secreted glycophosphoprotein osteopontin (OPN). In this study, we evaluate OPN as a serum marker of pancreatic adenocarcinoma. METHODS: In situ hybridization for OPN was performed on a pancreatic adenocarcinoma tissue microarray. Serum OPN levels were determined in preoperative sera from 50 patients with pancreatic cancer and 22 healthy control individuals by competitive ELISA. RESULTS: In situ hybridization for OPN performed on a tissue microarray revealed strong OPN mRNA signal in tumor-infiltrating macrophages in 8 of 14 pancreatic adenocarcinomas. In contrast, OPN expression was not seen in the pancreatic cancer cells themselves, nor was it seen in normal pancreatic tissue or in the macrophages distant from the infiltrating cancer. Serum OPN levels, as measured by ELISA, were elevated in the sera of 50 patients with resectable pancreatic adenocarcinoma compared to 22 healthy control individuals (mean +/- SD for OPN was 482 +/- 170 ng/ml and 204 +/- 65 ng/ml, respectively; P < 0.001). Using a cutoff level of 2 SD above the mean for healthy individuals, elevated OPN had sensitivity of 80% and specificity of 97% for pancreatic cancer. In contrast, only 62% of these patients with resectable pancreatic cancer had elevated CA19-9. CONCLUSIONS: Serum OPN may have utility as a diagnostic marker in patients with pancreatic cancer. 相似文献
42.
Wei Xin Ki J Yun Francesca Ricci Marianna Zahurak Wanglong Qiu Gloria H Su Charles J Yeo Ralph H Hruban Scott E Kern Christine A Iacobuzio-Donahue 《Clinical cancer research》2004,10(24):8516-8520
MKK4 (MAP2K4/SEK1) is a member of the mitogen-activated protein kinase family, originally identified as a kinase involved in the stress-activated protein kinase pathway by directly phosphorylating c-Jun NH2-terminal kinase. MKK4 genetic inactivation has been observed in a subset of pancreatic carcinomas, implicating deregulation of the stress-activated protein kinase pathway in pancreatic carcinogenesis. We evaluated Mkk4 protein expression patterns by immunohistochemical labeling in a series of 60 resected primary infiltrating pancreatic adenocarcinomas (24 cases with known MKK4 genetic status), and 14 different tissue arrays representing the primary carcinoma and all of the gross metastases from 26 patients that died of metastatic pancreatic cancer. Among the surgically resected carcinomas, focal or diffuse-positive immunolabeling for Mkk4 protein was found in 52 of 60 cases (86.7%). Among the eight carcinomas with negative Mkk4 immunolabeling, three harbored a homozygous deletion or intragenic mutation of the MKK4 gene, in contrast to none of the 52 cases with positive Mkk4 immunolabeling (P < 0.01). Loss of Mkk4 immunolabeling showed a trend toward shorter survival, with Mkk4-positive carcinomas having half the risk of death than Mkk4-negative carcinomas (P = 0.09). Mkk4 immunolabeling patterns were also evaluated among unresectable primary and metastatic cancer tissues from autopsy specimens, indicating intact Mkk4 immunolabeling in 88.8% of the unresectable primary carcinomas as compared with 63.3% of distant metastases (P < 0.001). Our data indicate that the loss of Mkk4 protein expression in pancreatic carcinomas may be more frequent than suggested by the rates of genetic inactivation alone and that MKK4 loss may contribute to disease progression. The correlation of MKK4 genetic status with immunolabeling patterns validate this approach for the evaluation of MKK4 status in routine histologic sections and may provide useful information regarding patient prognosis. 相似文献
43.
Anthony T C Chan Brigette B Y Ma Y M Dennis Lo S F Leung W H Kwan Edwin P Hui Tony S K Mok Michael Kam Lisa S Chan Samuel K W Chiu K H Yu K Y Cheung Karen Lai Maria Lai Frankie Mo Winnie Yeo Ann King Philip J Johnson Peter M L Teo Benny Zee 《Journal of clinical oncology》2004,22(15):3053-3060
PURPOSE: To assess the efficacy of neoadjuvant paclitaxel and carboplatin (TC) followed by concurrent cisplatin and radiotherapy (RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to monitor treatment response with plasma Epstein-Barr virus (EBV) DNA. PATIENTS AND METHODS: Thirty-one patients with International Union Against Cancer stages III and IV undifferentiated NPC had two cycles of paclitaxel (70 mg/m2 on days 1, 8, and 15) and carboplatin (area under the curve 6 mg/mL/min on day 1) on a 3-weekly cycle, followed by 6 to 8 weeks of cisplatin (40 mg/m2 weekly) and RT at 66 Gy in 2-Gy fractions. Plasma EBV DNA was measured serially using the real-time quantitative polymerase chain reaction method. Results All patients completed planned treatment. Response to neoadjuvant TC was as follows: 12 patients (39%) achieved partial response (PR) and 18 achieved (58%) complete response (CR) in regional nodes; five patients (16%) achieved PR and no patients achieved CR in nasopharynx. At 6 weeks after RT, one patient (3%) achieved PR and 30 patients (97%) achieved CR in regional nodes, and 31 patients (100%) achieved CR in nasopharynx; 29 patients (93%) had EBV DNA level of less than 500 copies/mL. Neoadjuvant TC was well tolerated, and the most common acute toxicity of cisplatin plus RT was grade 3 mucositis (55%). At median follow-up of 33.7 months (range, 7 to 39.3 months), six distant and three locoregional failures occurred. Plasma EBV DNA level increased significantly in eight of nine patients who experienced treatment failure but did not increase in those who did not. The 2-year overall and progression-free survival rates were 91.8% and 78.5%, respectively. CONCLUSION This strategy was feasible and resulted in excellent local tumor control. Serial plasma EBV DNA provides a noninvasive method of monitoring response in NPC. 相似文献
44.
Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. 总被引:5,自引:0,他引:5
45.
Anthony T. C. Chan Thomas W. T. Leung Wing H. Kwan Tony S. K. Mok Winnie Yeo Maria Lai Philip J. Johnson 《Cancer chemotherapy and pharmacology》1998,42(3):247-249
Purpose: A single-institution phase II trial of Temodal (temozolomide, SCH52365) in Chinese patients with advance nasopharyngeal
carcinoma was undertaken to determine the efficacy and safety of the drug in this population. Methods: A total of 14 patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma were entered into the study.
One patient was unevaluable. Temodal was given at doses of 150 or 200 mg/m2 daily on days 1–5 every 28 days. Results: In all, 30 cycles of Temodal were given with no significant toxicity. All 13 (100%) evaluable patients had progressive disease
after 2 (84.6%) or 4 (15.4%) courses. Conclusion: Temodal given on this schedule has no activity in advanced nasopharyngeal carcinoma.
Received: 9 January 1998 / Accepted: 4 February 1998 相似文献
46.
Emergency and elective embolotherapy of various systemic arteries in 64 patients was carried out at a tertiary centre of Armed Forces. Specific indications were haemoptysis (n=43), preoperative (n=18), haematuria (n=1), epistaxis (n=1) and chemoembolization (n=1). The procedures were performed with gelfoam pellets (n=46), gelfoam pellets and absolute alcohol (n=1), polyvinyl alcohol particles (PVA) (n=14), steel coils (n=2) and Adriamycin-in-oil emulsion (n=1). Embolotherapy resulted in complete haemostasis in 37 (82.2%) out of 45 cases of haemorrhage. In eight cases (17.8%), it resulted in significant improvement. Complete haemostasis was achieved in both cases of haematuria and epistaxis. Pre-operative embolotherapy resulted in considerable reduction of peroperative blood loss in all the cases. Chemoembolization of Hepatocellular carcinoma resulted in partial regression of the tumour. The purpose of this study was to assess the efficacy, safety and reliability of vascular embolotherapy for control of life threatening haemorrhage and preoperative reduction of lesions.KEY WORDS: Embolization, Embolotherapy, Haemorrhage 相似文献
47.
Donna E. Hansel Ayman Rahman Robb E. Wilentz Ie-ming Shih Michael T. McMaster Charles J. Yeo Anirban Maitra MD 《Journal of gastrointestinal cancer》2005,35(1):15-23
HLA-G belongs to the nonclassical MHC class Ib group of molecules and has been implicated in mediating immune-responsiveness in various cancerous and non-cancerous cell types. We have examined HLA-G expression in a number of human gastrointestinal malignancies, including pancreatic ductal adenocarcinoma, ampullary cancer, biliary cancer, and colorectal cancer by immunolabeling analysis. We used indices of <5% (negative), 6–25%, 26–50%, 51–75%, and >75% (diffuse) to subclassify lesions based on percentage of positive cell labeling. Across all cancer subtypes, 52–79% of lesions demonstrated expression of HLA-G, with up to 33% of lesions demonstrating diffuse (>75%) expression. In addition, we utilized the neoplastic progression model of colorectal cancer to evaluate HLA-G protein expression in normal colon, tubulovillous adenomas, invasive cancer, and liver metastases arising from colorectal cancer. Focal HLA-G expression was detected in regions of normal colon adjacent to sites of adenomatous and cancerous lesions, as well as in all stages of cancer progression. Overall, the percentage of diffusely (>75%) labeled lesions appeared increased in preneoplastic and neoplastic conditions, as compared to normal colon. Specifically, tubulovillous adnenomas demonstrated pronounced diffuse labeling in 58% of lesions examined. No correlation with HLA-G expression and CD4+ or CD8+ T cells was identified. We propose that HLA-G expression is upregulated in a large percentage of gastrointestinal lesions and may serve to mediate immuneresponsiveness in certain instances. 相似文献
48.
Yeo Kwon Yoon Jae Han Park Jiyoun Kim Seung Hwan Han Seung Hwan Shin Jin Woo Lee Kwang Hwan Park 《Clinics in Orthopedic Surgery》2022,14(2):289
BackgroundThe aim of this study was to evaluate clinical outcomes of sodium tetradecyl sulphate (STS) sclerotherapy for conservative treatment of lateral malleolar bursitis of the ankle.MethodsWe reviewed data from 20 consecutive patients (20 ankles) who underwent STS sclerotherapy between August 2018 and June 2019. After aspiration of fluid from the lateral malleolar bursal sac, 2 mL (20 mg) STS was injected into the sac. Clinical outcomes and side effects and complications were evaluated at 2 weeks, 3 months, 1 year, and 2 years after sclerotherapy. Responses to treatment were assessed according to degree of fluctuation, shrinkage of the bursal sac, and soft-tissue swelling. The 36-item short form survey (SF-36) was completed for each patient before and after therapy.ResultsComplete response was observed in 17 patients (85%), and partial response was observed in 3 patients (15%) after STS sclerotherapy. SF-36 physical component scores improved from 62.2 (interquartile range, 5.2) before therapy to 70.0 (interquartile range, 7.9) at last follow-up (p < 0.05). One patient (5%) experienced transient hyperpigmentation at the injection site. No major complications occurred.ConclusionsSTS sclerotherapy was an effective and safe treatment for patients with lateral malleolar bursitis of the ankle. 相似文献
49.
50.
用固相法合成了hF-GRP及其15个类似物。全部裂解均用三氟甲磺酸完成。产物总收率60%~80%。对所有合成肽进行了影响离体的小鼠垂体分泌LH的活性筛选。结果表明,当合成肽的浓度为0.05mmol/L时:(1)将hF-GRP的C端COOH变成CONH2,活性变化不大;(2)C端残基Asn14被Phe替换后刺激垂体分泌LH的活性明显高于hF-GRP;(3)Thr3被Tyr替换后片段hF-GRP(3~13)有抑制LH分泌的活性;(4)其余类似物与空白对照相似。 相似文献